Altech marks milestone as it pumps out novel battery anodes
Altech Batteries is pumping out its high-tech Silumina anodes from its German pilot plant, marking a milestone for the company as it supplies first product to potential customers for testing and sets itself up for future commercial production.
The new-age technology has achieved a significant breakthrough by coating silicon particles with a nanolayer of alumina. The high-tech particles are then sandwiched between graphite layers to form the anodes. The process has been shown to boost the energy capacity of lithium-ion batteries by 55 per cent.
The technology incorporates Altech's advanced alumina coating, as well as an optimised silicon content and the company's spherification method of forming silicon into sphere-shaped particles to provide a game-changing performance and a significant boost in the energy capacity.
Silicon use in battery anodes has had two major drawbacks. The particles can expand by up to 300 per cent while batteries charge, leading to swelling, fracturing and ultimately, battery failure. Silicon can also deactivate a high percentage of lithium-ions, thereby reducing battery performance and lifespan.
Altech says its testwork confirms that modifying the silicon particles with the alumina coating resolves these issues, which caused first-cycle capacity loss of up to 50 per cent. It notes its testwork shows stable battery and cycling performance. Initial issues with the dispersion of the silicon particles within the graphite mix were resolved by the spherification process.
The company has recently built a pilot plant in Saxony, Germany, adjacent to its proposed commercial project site, which is producing its Silumina anodes.
Altech is supplying anodes to several European vehicle manufacturers under non-disclosure agreements.
Silicon has about 10-times the energy retention capacity of graphite, making it an ideal addition to anodes to help mould the next-generation of lithium-ion batteries.
The significant increase in retention capacity from the high-tech improvement has resulted in a jump to about 500 milliampere hours per gram mass (mAh/g) for the company's anodes, in comparison to an average lithium-ion battery anode of 320mAh/g.
If customer testing proves successful, Altech may have kicked open a door and pushed itself to the head of a global queue for anode supplies to electric vehicle battery manufacturers.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Herald Sun
an hour ago
- Herald Sun
AUC on track for Katanning gold feasibility
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. AUC extends Datatine shoot at Katanning gold project Assays include grades up to 5.8g/t gold Project feasibility study due for release in late-June Special Report: Ausgold has extended the Datatine high-grade shoot by 240m down-plunge at its Katanning gold project (KGP) in WA. New results reinforce the potential of Datatine as a high-grade underground prospect and support a strong outlook for future resource growth at Katanning. The company is in the final stages of a feasibility study at the project, as it accelerates towards its goal of becoming Australia's next mid-tier gold producer. Plan map of the Katanning gold project. Pic: AUC The Datatine prospect hosts some of the highest gold grades within the project, previously returning grades of up to 11.47g/t. This final batch of assays from four reverse circulation-diamond and diamond drill holes have extended the Datatine shoot 240m down-plunge of the current Datatine resource. They returned a notable 6.6m at 3.40g/t gold from 362m, including 3.8m at 5.80g/t from 364.85m in BSRCD1805, the deepest hole in this program. Hole BSRCD1803 returned 2m at 3.67g/t from 297m along with 11.3m at 0.96g/t, including 4.2m at 1.81g/t from 333.83m. This hole, along with holes BSRCD1802 and BSDD049, returned intersections consistent with economic open pit grade intercepts. These results have informed an updated geological model for the high-grade mineralisation at Datatine. Datatine prospect-scale plan map with new drilling highlighted and aeromagnetic background. Pic: AUC Highlights underground mining potential Ausgold (ASX:AUC) will now utilise funding of up to $180,000 secured through Round 31 of the Geological Survey of Western Australia (GSWA) Exploration Incentive Scheme (EIS) to: Target sections where high-grade mineralisation is interpreted to have been missed; and Test for further high-grade mineralisation up to 150m beyond the current down-plunge extent. 'The latest assay results from Datatine continue to validate the potential for underground mining at Katanning,' AUC executive chairman John Dorward said. 'Results from BSRCD1805, which sit 240m down-plunge of the current resource, are particularly encouraging and support our strategy to pursue resource growth at depth. 'With both Datatine and the Central Zone remaining open down-plunge, we see clear opportunities to increase resources at the KGP and look forward to undertaking additional drilling at Datatine, supported by EIS co-funding, to follow-up this opportunity.' The company is on track to complete the project feasibility study considering the development of a large-scale, long-life open pit gold project at Katanning in late June. This article was developed in collaboration with Ausgold, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Ausgold reinforces Katanning underground potential with high-grade hits
West Australian
2 hours ago
- West Australian
Venus lands hefty 38g/t gold hit at promising WA Sandstone project
Venus Metals Corporation has tapped into a golden hot streak after new drilling at its promising Bellchambers and Rangeview prospects near Sandstone in Western Australia unearthed a sizzling 1m hit grading 38.3 grams per tonne (g/t) gold. The company's latest 34-hole reverse circulation drilling campaign, totalling 1749 metres, added more juice gold to its existing resource at Bellchambers and sharpened the exploration focus on the company's nearby Rangeview prospect. The results are expected to fast-track an updated resource estimate, potentially upgrading parts of the resource from indicated to measured status. Standout hits at Bellchambers include a juicy 19m grading 3.74g/t gold from just 11m downhole – with a blazing 1m at 38.3g/t – along with a 29m hit going 1.55g/t from 11m and 30m running at 1.72g/t from 45m. Over at Rangeview, the rig nailed 13m at 1.60g/t gold from 19m and a 18m find at 1.24g/t from 47m, spiced up by a 1m strike going 11.5g/t gold. Venus says the results hit the mark, backing up the known gold zones across both prospects. Notably, the drill campaign plugged key gaps in the existing Bellchambers resource, which already hosts 722,000 tonnes at 1.31g/t for a handy 30,500 ounces gold. Venus Metals holds a commanding 90 per cent stake in the 125-square-kilometre Bellchambers project, 23km southwest of Sandstone. It also holds 55 million shares worth more than $16 million in Rox Resources, which owns the nearby monster 2.3-million-ounce Youanmi gold project. Venus says the new results support its plans to push the project towards potential development, with near-surface oxide mineralisation at Bellchambers being a key focus for upcoming test work and metallurgical studies. A diamond drilling campaign is now in the pipeline to tighten resource estimates and gather fresh samples for processing studies. Adding to the reams of new data, the company is also collecting representative samples to validate metallurgical recoveries as a key step on the road to production. Structurally, gold at Bellchambers and Rangeview prospects is tied to quartz veins and sulphide-rich zones within sheared sedimentary and mafic rocks. The steeply dipping mineralisation runs down to about 45-50 metres, making it well-suited to open-pit mining. With a mine-gate sales agreement already in the mix with Rox Resources, Venus is well-positioned to potentially monetise its gold ounces without the heavy lifting of building a standalone plant. The Sandstone region, already peppered with historic gold workings, appears to be continuing to deliver for Venus. And with a refreshed resource estimate due in the next two months, punters may not have to wait long to see just how much more gold could be added to the ledger. This latest round of drilling has confirmed Bellchambers and Rangeview remain fertile hunting grounds and Venus is keeping the drill rigs warm for more discoveries. Is your ASX-listed company doing something interesting? Contact:
News.com.au
2 hours ago
- News.com.au
Health Check: Cochlear's ear-nings downgrade is not what investors wanted to hear
Cochlear downgrades full-year profit expectations, citing sluggish sound processor sales Mesoblast eyes second US drug approval sooner rather than later Who's for a bargain biotech … or three? Cochlear (ASX:COH) is banking on the rollout of new hearing devices to bolster earnings after today downgrading its full-year earnings expectations. The fourth biggest ASX-listed biotech, Cochlear now expects underlying net earnings of $390-400 million, compared with February's guidance at the 'lower end' of $410-430 million. Let's call it a 5% downgrade. Management had expected a single-digit decline in its services revenue – sound processors and the like – but now expects a fall in the high-single digit territory. The problem is that Nucleus 8 sound processor sales grew strongly post launch, but the buzz has abated. Users are unwilling to upgrade to tweaked variants such as the Kanso 'off the ear' processor. 'We continue to work on identifying and connecting with recipients who could benefit from the latest sound processing technology,' the company says. 'These initiatives, combined with the introduction of are expected to lift services revenue in the 2025-26 year.' Meanwhile, sales of the Cochlear implants remain robust and should increase by 10 per in the current year. But growth is weighted to emerging markets. 'Growth in the higher value developed markets has been impacted by slower-than-expected market growth and a small loss of market share in a few countries.' Smart implant launch dulls the pain Not all Cochlear's news was negative. Also today, Cochlear launched its Nucleus Nexa System, 'the world's first and only smart cochlear implant'. The device enables users to upgrade the firmware for both the implant and the related Nucleus 8 Nexa sound processor. Cochlear CEO Dig Howitt says Nexa results from 20 years of research and development. 'Similar to smartphones, the implant firmware can be updated to enable new features and access to future innovations.' After dipping 8% in early trade, Cochlear shares by noon were slightly higher ... so go figure. Buoyant Bioxyne bolsters revenue Bioxyne (ASX:BXN) this morning had a more encouraging update, upping full-year revenue expectations from $25 to $28 million. That's a 200% jump on last year's run rate. Bioxyne sells consumer health products – notably cannabis derived ones such as medicinal 'gummies'. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into producing psychedelic compounds for therapeutic use. The company was granted Australia's first Good Manufacturing Practice licence to produce psilocybin and MDMA ('molly', or ecstasy) Management cites Australian pharmaceutical manufacturing and supply as the key growth driver. "The company is making significant progress in Germany and the UK and will provide a market update shortly." Telix launches second imaging product Telix Pharmaceuticals (ASX:TLX) has launched its second commercial product in the US, also for prostate cancer. The tool, Gozellix, is a kit for preparing an injection of gallium-68 (gozetotide) to detect the tell-tale prostate-specific membrane antigen. The agent is relevant for prostate cancer patients suspected metastases and are candidates for initial definitive therapy. It is also intended for patients with suspected recurrence of prostate cancer based on an elevated serum prostate-specific antigen level. The US Food and Drug Administration (FDA) approved Gozellix in March 2025. The company says Gozellix has a shelf life of up to six hours, which makes it more flexible to use than other products based on the gallium-68 isotope. The company also claims Gozellix is 90% accurate in detecting metastases at the initial stage. In December 2021 the FDA approved Telix's first product, Illucix, which is also gallium-68 based. In calendar 2024 Telix reaped $783 million of revenue from Illucix, 70% higher. US Mesoblast-off for second product? Stem cell therapy developer Mesoblast (ASX:MSB) is confident the FDA will allow accelerated approval of its heart disease drug candidate, Revascor. The agency last December approved Mesoblast's Ryoncil for childhood graft-versus-host disease. That entrenches Ryoncil in the Biotech Hall of Fame as the first and only FDA-approved mesenchymal stromal stem cell product for any indication. Revascor is intended for the much larger market of patients with ischemic chronic heart failure, reduced ejection fraction and inflammation. In the first week of June, Mesoblast held a Type B meeting with FDA to discuss components of a potential filing for marketing approval. 'There was general alignment on items regarding chemistry, manufacturing and controls, potency assays for commercial product release and proposed design and primary endpoint for the confirmatory trial post-approval,' Mesoblast says. 'The company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing.' What's in the brokers' bargain bin? Investors are undervaluing at least three ASX biotech, according to broking analysts. Bell Potter rates Radiopharm Theranostics (ASX:RAD) a buy, citing an 'exceptionally positive outlook'. This follows yesterday's announcement of US Food and Drug Administration fast track approval for its metastatic brain cancer radiotherapy, RAD101. Radiopharm is trialling RAD101 in a 30 patient, phase II effort across five eastern Australian sites. Headline results are due in late 2025 – 'earlier than anticipated'. Bell Potter values the stock at 2.6 cents, compared with yesterday's close of half a cent. Macquarie Equities opines the Monash IVF Group (ASX:MVF) share sell off has been overdone following a second embryo mix-up 'incident'. In a note titled 'bargain hunting' – there's a clue – the firm values the stock at $1.30 a share, implying 100% upside. This is despite the shares recovering 10% this morning after CEO Michael Knaap resigned, leaving CFO Malik Jainudeen to fill the hot seat temporarily. Finally, Morgans values Imricor Medical Systems (ASX:IMR) at $2.28, a 40% increment on the current price. The company has developed the world's first cardiac ablation device that can be guided by magnetic resonance imaging. This week Imricor won European (CE Mark) approval for its Northstar Mapping System, a key component of its offering.
